Detalhe da pesquisa
1.
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Br J Haematol
; 192(3): 542-550, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207010